Diagnosis and management of type I and type V hyperlipoproteinemia

  • J Atheroscler Thromb. 2012;19(1):1-12. doi: 10.5551/jat.10702.
Takanari Gotoda  1 ,  Koji Shirai ,  Takao Ohta ,  Junji Kobayashi ,  Shinji Yokoyama ,  Shinichi Oikawa ,  Hideaki Bujo ,  Shun Ishibashi ,  Hidenori Arai ,  Shizuya Yamashita ,  Mariko Harada-Shiba ,  Masaaki Eto ,  Toshio Hayashi ,  Hirohito Sone ,  Hiroaki Suzuki ,  Nobuhiro Yamada ,  Research Committee for Primary Hyperlipidemia, Research on Measures against Intractable Diseases by the Ministry of Health, Labour and Welfare in Japan
Affiliations
  • 1. Department of Clinical and Molecular Epidemiology, 22nd Century Medical and Research Center, University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan. [email protected]
PMID: 22129523 DOI: 10.5551/jat.10702
Abstract

Both type I and type V hyperlipoproteinemia are characterized by severe hypertriglyceridemia due to an increase in chylomicrons. Type I hyperlipoproteinemia is caused by a decisive abnormality of the lipoprotein Lipase (LPL)- Apolipoprotein C-II system, whereas the cause of type V hyperlipoproteinemia is more complicated and more closely related to acquired environmental factors. Since the relationship of hypertriglyceridemia with atherosclerosis is not as clear as that of hypercholesterolemia, and since type I and V hyperlipoproteinemia are relatively rare, few guidelines for their diagnosis and treatment have been established; however, type I and V hyperlipoproteinemia are clinically important as underlying disorders of acute pancreatitis, and appropriate management is necessary to prevent or treat such complications. Against such a background, here we propose guidelines primarily concerning the diagnosis and management of type I and V hyperlipoproteinemia in Japanese.